

In our previous single dose two-period cross-over bioequivalence study for gefitinib generic products in dogs under fasting condition, the results also did not match the acceptance criteria. Analysis of variance (ANOVA) revealed that there were significant differences between two periods and between individuals. A single-oral-dose, two-period, cross-over bioequivalence study was carried out in 12 Beagle dogs, with a washout interval of 7 days, approximately 24 half-lives (Mckillop et al., 2004).